Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

InVivo Therapeutics Holdings Corp (NASDAQ:NVIV)

Friday’s Trading Day
8.64 +0.09 / +1.05%
As of Oct 02
Day’s Change
Monday’s Pre-Market   Switch to standard view »
8.65 +0.01 / +0.12%
Volume: --
Industrial Services
Engineering & Construction

Company Description

Invivo Therapeutics Holdings Corp. is a medical device company, which develops and commercializes groundbreaking technologies for the treatment of spinal cord injuries. Its platform technologies focus on minimizing tissue damage sustained following acute injury and promoting neural plasticity of the spared healthy tissue, which may result in full or partial functional recovery. The company intends to leverage its primary platform technology to develop and commercialize three products: a biocompatible polymer scaffolding device to treat acute spinal cord injuries; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute spinal cord injuries and a biocompatible polymer scaffolding device seeded with autologous human neural stem cells to treat acute and chronic spinal cord injuries. Its additional applications of platform technologies include the potential treatment for, spinal cord injury following tumor removal, peripheral nerve damage, and postsurgical treatment of any transected nerve. Invivo Therapeutics Holdings was founded by Joseph P. Vacanti, Frank M. Reynolds and Robert Langer on November 28, 2005 and is headquartered in Cambridge, MA.

Contact Information

Invivo Therapeutics Holdings Corp.
One Kendall Square
Cambridge Massachusetts 02139
P:(617) 863-5500
Investor Relations:



Mutual fund holders8.19%
Other institutional7.36%
Individual stakeholders0.02%

Top Executives

Mark D. PerrinChairman & Chief Executive Officer
William D'AgostinoSenior Vice President-Operations
Steven F. McAllisterChief Financial Officer
Kristin NeffVP-Clinical Operations & Project Management
Thomas R. UlichChief Scientific Officer